Wugen
Dr. Lewis has over 10 years of biotechnology and oncology research experience. Before joining Wugen, Dr. Lewis was appointed Venture Capital Fellow at BioGenerator (2018-2019), an evergreen investor that creates, develops and funds innovative companies and entrepreneurs in the St. Louis region. Prior to completing his doctoral work, Dr. Lewis held several positions at Monsanto Company (2006-2013), leading efforts to validate and implement novel sequencing technologies and on-board data management systems.
Dr. Lewis received his Ph.D. in Molecular Biology and M.Sc. in Biology from the Washington University in St. Louis and his B.Sc. in Biochemistry from the Eastern Connecticut State University.
Wugen
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.